The aim of this study was to establish the prevalence of c-Ki-ras mutations in codons 12 and 13 in surgically resected Barrett's adenocarcinomas and associated preneoplastic lesions.
Methods

TUMOUR SAMPLES
Twenty eight surgically resected specimens were collected from patients with Barrett's adenocarcinoma who underwent surgery at Beaujon hospital between 1990 and 1994. Of these specimens, 25 were from men and three from women. None of the patients had undergone chemo-or radiotherapy before surgery. All of the surgical specimens were received fresh, and samples of adenocarcinoma (in all cases) and of Barrett's mucosa adjacent to the tumour (in 18 cases (nine non-dysplastic, three with low and six with high grade dysplasia)) were snap frozen and stored in liquid nitrogen until DNA extraction was performed. The resected Barrett's oesophagus was then fixed in 10% neutral formalin and analysed for tumour stage and the grade of dysplasia in the surrounding mucosa.
c-KI-RAs MUTATION ANALYSIS
Genomic DNA was extracted with sodium dodecyl sulfate/proteinase K using the phenol chloroform method. Detection of mutations in codons 12 and 13 of the c-Ki-ras gene was carried out using polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism (RFLP) analysis as described by Jiang et al. 4 Briefly, the primer sequences contained an altered base pair that artificially created restriction sites adjacent to or within the wild-type region of codons 12 or 13. Mutations were then scored by loss of the restriction pattern after digestion with the appropriate restriction endonuclease (BstNI at codon 12 and HaeIII at codon 13). All specimens were re-evaluated in a second, separate PCR amplification. Human colon carcinoma cell lines with well characterised mutations in codons 12 (SW480) and 13 (HCT1 16, LOVO) were used as positive controls.
Results
The specificities and sensitivities of both of these assays were first evaluated as described by Jiang et al. 4 For both exons, the mutated band was still detectable at a 1 in 100 dilution. Therefore, the threshold of detection was one cell with a homozygous mutation in 102 cells with a wild-type c-Ki-ras gene. 
Cancer developing in Barrett's oesophagus shares some similarities with that observed in ulcerative colitis. Both diseases are clinically characterised by a chronic inflammation of the mucosa, an increased incidence rate of adenocarcinoma, and a multistep carcinogenesis with dysplasia as the precursor lesion of adenocarcinoma. Our results suggest that the carcinogenic process arising in Barrett's oesophagus could be compared with that of colon cancer arising in ulcerative colitis. Specific genetic events underlying cancer arising in ulcerative colitis and sporadic colorectal cancer are different. In sporadic colorectal carcinoma c-Ki-ras gene mutation is a frequent event and appears to occur at an early stage in the adenoma-carcinoma sequence, while TP53 gene mutation is a frequent but late event.8 However, colon cancer complicating ulcerative colitis and Barrett's adenocarcinoma are genetically characterised by a lower prevalence rate of c-Ki-ras mutation, and early and frequent mutations in TP53 gene. 27910 The results of this study suggest that the c-Ki-ras oncogene is not activated in adenocarcinoma arising in Barrett's oesophagus and underlines the need to identify other genetic events for screening those patients with Barrett's oesophagus at high risk of developing cancer. 
